David Buscher, M.D.
8195 166th Ave NE, Suite 101
Redmond, WA 98052
Phone: 425-284-1586
  • Home
  • About
  • Environmental Medicine
  • Allergies
  • Cardiovascular Disease
  • Therapies Offered
Landscape
The Northwest Center
for Environmental Medicine

Comprehensive Allergy Evaluation and Treatment
Noninvasive Cardiovascular Disease Intervention
Individual, Family and Group Counseling
Allergies
  • Inhalant Allergy
  • Food Allergy
  • Treatments
  • Low-Dose Allergy treatment (LDA)
  • Dust/Mite Control

Low-Dose Allergy treatment (LDA)

LDA may be the best possible treatment for complex allergy patients and for those with less complex problem such as hay fever.  LDA is a method of allergy desensitization using combinations of a variety of extremely low dose allergens (approximately 10-6 to 10-17). This ultra low-dose mixture of antigens is given with a minute dose of beta glucuronidase.  Together this combination stimulates production of T-suppressor cells, which then "turn off" T-helper cells that are mistakenly causing the body to overreact to substances. LDA treatment works differently than classic immunotherapy. Classic immunotherapy is largely antibody-mediated, while LDA appears to be cell-mediated, likely acting on certain T cells. 

LDA is used to treat all types of allergies including inhalants, foods and chemicals. The treatment can be used to treat seasonal and perennial hay fever, asthma, food allergies and many other conditions caused by allergy.

LDA includes mixtures of over 300 allergens that act "universally".  This means that patients who have widespread allergies to many different substances causing a wide diversity of symptoms can respond favorably to the treatment.  
The LDA mixtures include pollens, animal danders, dust and dust mites, fungi, Candida, molds, foods, food additives, perfumes and common chemicals (not pesticides and herbicides).

Frequency of Treatment

LDA is administered by injection into the forearm immediately after mixing at the doctor's office. A total volume 0.05 ml is injected, which feels like a bee sting.  Following the injection there may be an area of redness and swelling at injection site that resolves fairly quickly, but sometimes lasts for a day or more.  This is not harmful.

LDA treatments need only be given every 2-3 months at first, then less often.  Generally, patients are treated every 2-3 months about 6-8 times.  After that, treatments usually decrease to every 3-6 months and then less often.  When therapy reaches once a year, treatments are given less often after that.

Seasonal allergies, i.e. hay fever, strictly due to seasonal pollen allergy is initially treated with 2 doses per year and then only once annually just before the pollen season starts.  It is preferable to get the first injection 2 months before the onset of the season and a booster dose 2-3 weeks just before the season begins. Booster doses are given once a year after that.

Other allergies including food intolerance are more complicated.  Initial doses are given every 2-3 months with the first 12-18 months of treatment.  Subsequently the frequency of the desensitization can be reduced.  LDA injections cannot be given more than every 7-8 weeks.  When a favorable response is well-established, generally between the sixth to eighth dose (fewer doses in children), the frequency of treatment for most conditions may often be diminished to between 2-4 times per year.

Disadvantages of LDA

The main disadvantage of LDA is that it generally takes 6-8 injections to achieve a sustained effect that lasts for most of the 1-3 months between injections (except for the simple dust and pollen allergy, which requires fewer injections).
Another difficulty is that patients have to follow a specific protocol during the "3 critical days" when the LDA is given.  This includes a restricted diet, avoidance of specific allergens/chemicals and taking specific medications and supplements.

Development of LDA

EPD was developed in England by Dr. Len McEwen a brilliant British physician/immunologist.  Over 2000 patients in the US and approximately 350,000 worldwide utilized EPD safely and effectively.  In 2001 the FDA stopped usage of EPD in the US.   W.A. Shrader, M.D., who did the most too introduce EPD to physicians in the US formulated LDA, which uses the same active components as EPD does. In addition, Dr. Shrader added many more pollens, foods and other allergens more suited to the US.  LDA is compounded by a compounding pharmacy in the USA.  The FDA has been told by the Supreme Court that it cannot regulate compounding pharmacies the same as it regulates "manufactured" (retail) drugs, so compounding pharmacies are allowed to compound specific "compounds" that physicians prescribe, the same as they have done since the very beginning of medicine in this country.
© Copyright 2007 David Buscher, M.D.
All Rights Reserved.
Powered by Compass Web Publisher